Fig. 1: The enhanced antiviral activity of branched P9R (8P9R).
From: Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2
a The schematic figure of single P9R binding to single viral particle and branched P9R (8P9R) cross-linking viruses together. b The binding of 8P9R and P9R to SARS-CoV-2 and H1N1 viruses. Peptides coated on ELISA plates could capture virus particles which were then quantified by RT-qPCR. P9RS was the negative control peptide with no viral binding ability. Relative binding and P values were compared to P9R. Data are presented as mean ± SD of three independent experiments. c SARS-CoV-2 was pretreated with the indicated peptides for plaque reduction assay. Data are presented as mean ± SD of four independent experiments. d SARS-CoV-2 was treated by indicated peptides (25 μg ml−1) during viral inoculation. Viral RNA copies were detected by RT-qPCR at 24 h post infection in the supernatant of Vero-E6 cells. Data are presented as mean ± SD of three independent experiments. e SARS-CoV-2 was treated by peptides (50 μg ml−1) at 6 h post infection. Viral titers were measured at the indicated time by plaque assay. Data are presented as mean ± SD of three independent experiments. P values were compared with BSA. f Hemolysis assay of 8P9R in turkey red blood cells (TRBC). TRBC were treated by the indicated concentration of 8P9R. Hemolysis (%) was normalized to TRBC treated by Triton X-100. Data are presented as mean ± SD three independent experiments. P values are calculated by two-tailed student t test. ** indicates P < 0.01.Source data are provided as a Source Data file.
